Costa Rica : Intrexon, Ziopharm strike deal with University of Texas' MD Anderson Cancer Center.
Cutting in on the fervor over a new class of immunotherapies for cancer, Partners Intrexon and Ziopharm have signed an agreement with the University of Texas' MD Anderson Cancer Center.
The deal will see the partners giving $100 million to MD Anderson for a CAR-T technology, made through a process in which researchers remove T cells from a patient's blood and provide them with targeting mechanisms called chimeric antigen receptors (CARs), which seek out and bind to proteins that cancer cells express.
The ensuing cells are re-entered into the patient, at which point they find out malignancies and attack them as they would any normal infection.
MD Anderson's approach, called Sleeping Beauty, makes use of a nonviral gene transfer system to get those modified T cells to their targets, in contrast to major CAR-T therapies from Novartis ($NVS), Juno Therapeutics ($JUNO), Kite Pharma ($KITE) and others.
Researchers say, that offers some safety benefits, as MD Anderson's approach has so far avoided some of the harmful immune responses that have afflicted competing CAR-T programs.
2014 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 16, 2015|
|Previous Article:||China : AVIC Aircraft Company selects AMETEK fuel gauging system for MA700 turboprop.|
|Next Article:||Germany : Evonik launches DEGALAN VP P 34, a new heat-sealing binder, on the market.|